[Cutaneous rash from the use of medicine for rheumatoid arthritis].
Hannuksela
Matti
M
Kymenlaakson keskussairaala, ihosairauksien yksikkö, Kotka. matti.hannuksela@pp.fimnet.fi
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy*; D003875:Drug Eruptions / Q000175:diagnosis* / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005387:Finland; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment; D012720:Severity of Illness Index; D014010:Tinea Versicolor / Q000139:chemically induced* / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab